Masimo (MASI) has consistently beaten earnings estimates and is projected to continue this trend.

From Nasdaq: 2025-04-18 12:10:00

Masimo (MASI), a medical technology company in the Zacks Medical – Instruments industry, has consistently beaten earnings estimates. In the last two quarters, it surpassed estimates by 18.74% on average. For the most recent quarter, Masimo reported $1.80 per share, beating the expected $1.49 by 20.81%.

The positive trend in earnings estimates for Masimo suggests a potential earnings beat in the next quarterly report. With a Zacks Rank #1 (Strong Buy) and Earnings ESP of +0.64%, analysts are bullish on the company’s earnings prospects. When combined, these factors indicate a high chance of another beat.

Global semiconductor manufacturing is projected to grow significantly, presenting opportunities for top chip stocks. With expanding customer base and strong earnings growth, the new top chip stock recommended by Zacks is positioned to benefit from the increasing demand for Artificial Intelligence, Machine Learning, and Internet of Things.



Read more at Nasdaq: Why Masimo (MASI) Could Beat Earnings Estimates Again